Treatment Shortening of MDR-TB Using Existing and New Drugs

NCT02619994 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

214

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis, Multidrug-Resistant

Interventions

DRUG: Linezolid
DRUG: Delamanid
DRUG: Levofloxacin
DRUG: Pyrazinamide
DRUG: Locally-used WHO-approved MDR-TB regimen in Korea

Sponsor

Seoul National University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]